On September 4, HUTCHMED rose 5.3% in regular trading, trading at HKD 23.02 per share with turnover of HKD 118 million, extending the previous session's strong momentum.

The rally is a continuation of market enthusiasm following the company's announcement on September 3 of an exclusive development and licensing agreement with a GSK subsidiary for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted conjugate drug candidate. Under the agreement, GSK receives worldwide rights excluding mainland China, Hong Kong, Macau, and Taiwan to develop and commercialize the asset. The deal includes a USD 110 million upfront payment, with potential development, regulatory, and commercialization milestone payments totaling up to USD 1.295 billion, plus tiered royalties on net sales. Clinical development will initially focus on colorectal, pancreatic, and lung cancers, with the global Phase I program expected to commence in the second half of the year. The announcement drove shares up over 16% on September 3, and the current session's gain reflects sustained positive sentiment toward this landmark out-licensing transaction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)